BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05155085 (Lirentelimab in Atopic Dermatitis): BVCT ex-ante prediction vs. reported outcome

On 6 Jun 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 16 Jan 2024 readout is classified on the dashboard as False Positive (FP), a missed prediction. Recorded clinical-benefit conclusion: statistically insignificant commercially insufficient.

Clinical Trial

NCTID
NCT05155085
Acronym
ATLAS
Drug Name
Lirentelimab (AK002)
Drug MoA
SIGLEC8 mAb inhibitor
Drug Modality
monoclonal antibody (mAb)
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Atopic Dermatitis
Human Patients
131
Sponsor
Allakos
Phase
Phase 2

Prediction of , index 1089

Prospective Prediction
Prediction Index
1089
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit for refractory patients superior to omalizumab)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
224 days in advance
Readout Data Interpretation
primary endpoint not met.
Press Release
Prediction Result
Prediction Accuracy
Missed Prediction
Due to
due to suboptimal drug MoA modelling that has been permanently corrected.
Clinical Benefit Conclusion
statistically insignificant commercially insufficient
Prediction Classification
False Positive (FP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments
Phase
Phase 2
Status
Terminated
Enrollment
131
Lead sponsor
Allakos Inc.
Conditions
Atopic Dermatitis
Interventions
DRUG: AK002; OTHER: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-06-27
Primary completion
2023-12-18
Completion
2024-04-17
Results first posted
2024-09-24
Primary outcomes
  • The Proportion of Subjects Who Achieve 75% Improvement on the Eczema Area and Severity Index (EASI-75) at Week 14 (Baseline to Week 14)

NCT05155085 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials